Analyst consensus rating
ALX Oncology Holdings Analyst Rating: none
Direct answer
ALX Oncology Holdings's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.60.
Forecast evidence checked September 16, 2026.
Get free ALX Oncology Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.89
- Average price target
- $4.60
- High price target
- $6.00
- Low price target
- $4.00
- Low target gap
- +111.6%
- Target upside
- +143.4%
- High target gap
- +217.5%
- Target range width
- 105.8%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- September 16, 2026
- Valid through
- September 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ALX Oncology Holdings?
ALX Oncology Holdings has a verified none consensus. The same dataset has an average price target of $4.60.
How far are ALX Oncology Holdings's low and high targets from the recorded price?
The low target implies +111.6%, while the high target implies +217.5%.
How many analysts are included in ALX Oncology Holdings's consensus?
The verified consensus includes 5 analysts.
How is ALX Oncology Holdings's target upside or downside calculated?
The average target of $4.60 is divided by the recorded price of $1.89, then one is subtracted to produce +143.4%. This does not guarantee a future return.
When was ALX Oncology Holdings's analyst forecast verified?
The data was verified on 2026-09-16. The dataset is valid through 2026-09-23.